• 1
    Kalams SA, Buchbinder SP, Rosenberg ES et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73:671520.
  • 2
    Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:2199204.
  • 3
    Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:144750.
  • 4
    Pitcher CJ, Quittner C, Peterson DM et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:51825.
  • 5
    Wilson JD, Imami N, Watkins A et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000; 182:7928.
  • 6
    McNeil AC, Shupert WL, Iyasere CA et al. High level HIV-1 viremia suppresses viral antigen-specific CD4+ T cells proliferation. Proc Natl Acad Sci USA 2001; 98:1387883.
  • 7
    Palmer BE, Boritz E, Blyveis N, Wilson CC. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4+ T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol 2002; 76:592536.
  • 8
    Scott ZA, Beaumier CM, Sharkey M, Stevenson M, Luzuriaga K. HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol 2003; 170:578692.
  • 9
    Oxenius A, Price DA, Easterbrook PJ et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97:33827.
  • 10
    Malhotra U, Berrey MM, Huang Y et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181:12131.
  • 11
    Lori F, Jessen H, Lieberman J et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999; 180:182732.
  • 12
    Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001; 183:65761.
  • 13
    Westrop SJ, Qazi NA, Pido-Lopez J et al. Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers. PLoS ONE 2009; 4:e5474.
  • 14
    Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals. JAMA 2010; 304:194201.
  • 15
    Chakraborty R, Morel A-S, Sutton JK et al. Correlates of delayed disease progression in HIV-1-infected Kenyan children. J Immunol 2005; 174:81919.
  • 16
    Feeney ME, Draenert R, Roosevelt KA et al. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol 2003; 171:696875.
  • 17
    Papasavvas E, Sandberg JK, Rutstein R et al. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression. J Infect Dis 2003; 188:87382.
  • 18
    Hainaut M, Ducarme M, Schandene L et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003; 22:6270.
  • 19
    Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007; 4:3918.
  • 20
    Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:1126.
  • 21
    Correa R, Harari A, Vallelian F, Resino S, Munoz-Fernandez MA, Pantaleo G. Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. AIDS 2007; 21:2330.
  • 22
    Rinaldo CR, Liebmann JM, Huang X-L et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:32936.
  • 23
    Angel JB, Parato KG, Kumar A et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001; 183:54654.
  • 24
    Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. J Infect Dis 2001; 184:126878.
  • 25
    Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76:901123.
  • 26
    Clerici M, Shearer G. A TH1[RIGHTWARDS ARROW]TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:10711.
  • 27
    Vigano A, Balotta C, Trabattoni D et al. Long-term resistance to HIV infection in vertical HIV infection: cytokine production, HIV isolation, and HIV phenotype define long-term resistant hosts. Pathobiology 1997; 65:16976.
  • 28
    Bailer RT, Holloway A, Sun J et al. IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. J Immunol 1999; 162:753442.
  • 29
    Resino S, Bellón JM, Gurbindo D, Muñoz-Fernández MA. Disruption in cytokine and chemokine production by T-cells in vertically HIV-1-infected children. Acta Paediatr 2001; 90:98997.
  • 30
    Klein SA, Dobmeyer JM, Dobmeyer TS et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997; 11:11118.
  • 31
    Resino S, Galán I, Pérez A et al. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol 2004; 137:5707.
  • 32
    Resino S, Correa R, Bellón JM, Sánchez-Rámon S, Muñoz-Fernandez MA. Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS. AIDS Res Hum Retroviruses 2002; 18:1395406.
  • 33
    Huang S, Dunkley J, Tang Y et al. Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment. J Immunol 2008; 181:810311.
  • 34
    Tu W, Chen S, Sharp M et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004; 172:32607.
  • 35
    Goetghebuer T, Haelterman E, Le Chenadec J et al. Effect of early antiretroviral therapy on the risk of aids/death in HIV-infected infants. AIDS 2009; 23:597604.
  • 36
    Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:223344.
  • 37
    Rigaud M, Borkowsky W, Muresan P et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008; 198:112330.
  • 38
    Pensieroso S, Cagigi A, Palma P et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009; 106:793944.